AVRA Medical Robotics, Inc.

Financial performance has remained strong, with revenue growing from $0.00 in Q4 2022 to $1.43M in Q3 2023. Gross profit continued to perform well, with margins at 11% in the latest quarter. Operating income reached -$1.97M in Q3 2023, holding a steady -138% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.97M. Net income dropped to -$1.98M, keeping EPS at -$0.01. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.